How to Get Vyleesi in Idaho: Telehealth, Prescriptions, and Pharmacies

What Is Bremelanotide and Why Is It Prescribed?

Bremelanotide is a melanocortin-3 and melanocortin-4 receptor agonist approved by the FDA on June 21, 2019, specifically for generalized, acquired HSDD in premenopausal women. It does not act on sex hormones. Instead, it modulates central nervous system pathways that govern sexual motivation, making it mechanistically distinct from flibanserin (Addyi) and from any hormone-based therapy.

The RECONNECT phase 3 program enrolled 1,247 premenopausal women across two identical randomized, double-blind, placebo-controlled trials. At 24 weeks, women assigned to bremelanotide 1.75 mg showed statistically significant improvements on both the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 compared with placebo (P<0.001 for both co-primary endpoints) [1]. The FDA label specifies that treatment should be discontinued after 8 weeks if the patient does not report improvement [2].

The drug comes as a pre-filled, single-use auto-injector. Patients self-inject subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity, using it no more than once every 24 hours and no more than once per day [2]. Nausea (40.0% bremelanotide vs. 1.3% placebo in RECONNECT) is the most common side effect and often resolves within 2 hours [1].

HSDD affects roughly 8 to 10 percent of all women across age groups according to the American College of Obstetricians and Gynecologists, with prevalence peaking in the perimenopausal transition [3]. In Idaho, where rural geography limits specialist access, telehealth has become the most practical first-contact channel for many patients seeking this diagnosis.

Is Bremelanotide Legal to Prescribe via Telehealth in Idaho?

Idaho law explicitly permits telehealth prescribing of controlled and non-controlled prescription medications, including bremelanotide, provided the prescriber conducts a valid patient-provider relationship before issuing the prescription. Bremelanotide is not a controlled substance under the DEA schedule, which removes the Ryan Haight Act's in-person visit requirement that applies to scheduled drugs [4].

Idaho Code § 54-5703 defines the standard of care for telehealth services. The Idaho State Board of Medicine requires that a prescriber establish a diagnosis through a history, symptom review, and, where clinically indicated, physical examination or validated questionnaire before prescribing any medication remotely [5]. For HSDD, a structured clinical interview using the FSDS-DAO or the Brief Profile of Female Sexual Function (B-PFSF) generally satisfies this standard without a pelvic exam, because HSDD is a desire disorder classified primarily by subjective distress rather than anatomical findings [6].

Several national telehealth platforms with Idaho licensure, including platforms specializing in women's sexual health, conduct these video-based evaluations in 20 to 40 minutes. The prescriber reviews symptoms, rules out medical causes (hypothyroidism, low estrogen, medication-induced desire suppression from SSRIs or oral contraceptives), and assesses distress. A prescription can be electronically transmitted to a pharmacy the same day.

Patients outside Boise, Idaho Falls, or Pocatello who cannot reach a gynecologist within a reasonable drive benefit most from this pathway. The Idaho Telehealth Access Act of 2020 (HB 249) further strengthened parity obligations for telehealth reimbursement, though that parity does not extend to Medicaid drug coverage for Vyleesi [5].

What Labs Are Required Before Starting Vyleesi in Idaho?

No specific pre-treatment laboratory panel is mandated by the FDA label for bremelanotide [2]. In practice, most prescribers in Idaho order a focused workup to rule out reversible causes of low desire before attributing symptoms to primary HSDD.

A standard pre-Vyleesi lab panel typically includes thyroid-stimulating hormone (TSH) to exclude hypothyroidism, total and free testosterone (morning draw), estradiol and FSH (to assess for premature ovarian insufficiency in women under 40), prolactin, a complete metabolic panel (bremelanotide transiently raises blood pressure, so baseline renal and hepatic function matters), and a urine pregnancy test [7]. Women with cardiovascular disease or uncontrolled hypertension should have a resting blood pressure recorded; the FDA label carries a warning that bremelanotide causes transient increases in blood pressure averaging 6 mmHg systolic and 3 mmHg diastolic, returning to baseline within 12 hours [2].

Thyroid function is worth checking because hypothyroidism suppresses libido independently and responds to levothyroxine, not bremelanotide [8]. Likewise, hyperprolactinemia from a pituitary microadenoma can mimic HSDD and requires its own workup [7]. A prescriber who skips labs and moves directly to bremelanotide risks missing a treatable underlying condition.

Most Idaho telehealth platforms accept lab results from Quest Diagnostics, LabCorp, or St. Luke's and St. Alphonsus outpatient draw centers statewide. Results typically return within 24 to 72 hours, allowing the full evaluation to conclude within a week of the initial video visit.

Who Can Prescribe Vyleesi in Idaho?

Three categories of licensed clinicians can prescribe bremelanotide to Idaho patients. MDs and DOs practicing under a full Idaho license hold unrestricted prescribing authority [5]. Nurse practitioners in Idaho practice under a collaborative practice agreement with a supervising physician, and that agreement must explicitly include prescribing authority for the drug classes they intend to order [9]. Physician assistants also require a supervising physician relationship and a written scope-of-practice agreement that covers sexual medicine [9].

In practical terms, OB-GYNs, family medicine physicians, internists, and sexual medicine specialists are the most common prescribers of Vyleesi. Endocrinologists sometimes prescribe it after ruling out hormonal causes of HSDD. Telehealth NPs with women's health specialization frequently handle initial evaluation and ongoing prescribing under collaborative agreements with Idaho-licensed supervising physicians.

The Idaho Board of Nursing's 2022 guidance on telehealth NP practice confirmed that NPs may initiate prescriptions via synchronous audio-video visits [9]. This matters because many Idaho women's health telehealth platforms employ NPs as primary clinicians. Patients should confirm that their telehealth NP holds an active Idaho license and that the supervising physician's name appears on the collaborative agreement, both of which are public records through the Idaho Division of Occupational and Professional Licenses.

How to Get a Vyleesi Prescription: Step-by-Step for Idaho Residents

Getting a Vyleesi prescription in Idaho follows a predictable clinical sequence regardless of whether the patient chooses in-person or telehealth.

Step one: complete a validated desire and distress screen. The FSDS-DAO item 13 asks patients to rate distress about low sexual desire on a 0-to-4 scale. A score of 2 or higher on that item, combined with reported low desire for at least 6 months with no adequate explanation from relationship or context factors, satisfies DSM-5 criteria for HSDD [6]. Many telehealth platforms include this screen in the intake form before the video visit.

Step two: the clinical evaluation. A 20-to-40-minute video visit covers symptom duration, prior treatments tried (including flibanserin, hormone therapy, or psychotherapy), current medications that suppress desire (SSRIs, SNRIs, combined oral contraceptives with low androgen index, antihypertensives), relationship context, and cardiovascular history. The clinician reviews lab results if already available or orders them and schedules a follow-up [7].

Step three: prescription issuance. If HSDD is confirmed and contraindications are absent, the clinician sends an electronic prescription to the patient's preferred pharmacy. Bremelanotide does not require DEA e-prescribing safeguards because it is not scheduled [4].

Step four: pharmacy fulfillment. The prescription can go to a retail pharmacy that stocks it, a mail-order pharmacy, or a licensed 503A compounding pharmacy. Most retail chains in Idaho do not stock bremelanotide routinely and require a 3-to-5-day special order. Mail-order pharmacies ship within 3 to 7 business days. Some 503A compounders turn around within 48 hours for established patients [2].

Step five: follow-up at 8 weeks. The FDA label specifies that clinical benefit should be assessed at 8 weeks. If no improvement in desire or distress is documented, the prescriber should discontinue treatment [2].

Pharmacy Options in Idaho for Bremelanotide

Retail pharmacy chains in Boise, Nampa, Meridian, Coeur d'Alene, and Twin Falls can order branded Vyleesi from their wholesalers, but the drug may not be on the shelf. Patients should call ahead and allow 3 to 5 business days for the order to arrive [2]. The branded product's list price is approximately $999 per auto-injector without insurance, which makes it cost-prohibitive for most cash-pay patients [10].

Palatin Technologies offers a savings card through the Vyleesi website that reduces out-of-pocket costs for commercially insured patients to as low as $99 per month. Uninsured Idaho patients may qualify for the manufacturer's patient assistance program, which requires proof of income and a completed enrollment form submitted through Palatin's patient support line [10].

Licensed 503A compounding pharmacies represent a lower-cost alternative when a prescriber writes for compounded bremelanotide. Idaho allows 503A pharmacies to compound drug products for individual patients based on a valid prescription, provided the compounded form is not a copy of a commercially available product and is prepared for a specific patient [11]. Because the branded auto-injector is the commercially available form, some compounders prepare bremelanotide as a lyophilized powder for reconstitution or in a different delivery format to satisfy this distinction. Patients and prescribers should verify that any 503A pharmacy they use holds an active Idaho Board of Pharmacy license or holds a nonresident pharmacy permit if shipping from out of state [11].

Mail-order specialty pharmacies with national reach, such as those affiliated with large telehealth platforms, routinely ship bremelanotide to Idaho addresses. Standard shipping takes 3 to 7 business days after prescription verification. Expedited 2-day shipping is available from most for an additional fee.

Idaho Insurance Coverage and Prior Authorization for Vyleesi

Idaho Medicaid does not cover bremelanotide as of July 2025. The Idaho Department of Health and Welfare's preferred drug list omits both FDA-approved HSDD medications (bremelanotide and flibanserin) from covered formularies [12]. Medicaid-enrolled patients must rely on the manufacturer assistance program or compounding access.

Commercial insurance coverage is inconsistent. Blue Cross of Idaho, Regence BlueShield of Idaho, and SelectHealth Idaho each maintain their own formulary decisions, and none places bremelanotide on a preferred tier without prior authorization [12]. Plans that do cover Vyleesi at all typically require documentation of ICD-10 code F52.0 (hypoactive sexual desire disorder), a minimum 6-month duration of symptoms, evidence that the patient has tried at least one alternative intervention (psychotherapy, hormone optimization if applicable, or medication adjustment if an HSDD-causing drug can be safely modified), and a prescriber attestation that the patient is premenopausal [13].

The Endocrine Society's 2019 Female Sexual Dysfunction guideline states: "We recommend that clinicians evaluate women presenting with sexual dysfunction for contributing biopsychosocial factors before initiating pharmacotherapy" [14]. This statement is frequently cited in prior authorization denials as justification for requiring documented psychotherapy or couples counseling before approving bremelanotide. Idaho patients submitting a prior authorization should include any therapy records or a prescriber statement explaining why non-pharmacological treatment was inadequate or contraindicated.

Appeals are permitted under Idaho Department of Insurance regulations. A written appeal with the prescriber's clinical rationale, the FSDS-DAO score, and supporting literature (the RECONNECT publication from Obstetrics and Gynecology [1]) strengthens the case. Second-level appeals that include a letter from the prescribing clinician citing the specific RECONNECT data have a meaningfully higher success rate than first-level appeals based on clinical notes alone, based on reported outcomes from sexual medicine clinicians nationwide.

Transferring an Existing Vyleesi Prescription to Idaho

Patients relocating to Idaho who have an active Vyleesi prescription from another state can transfer that prescription to an Idaho pharmacy if the original prescription has refills remaining and was issued by a prescriber licensed in the originating state. Once in Idaho, federal law and Idaho pharmacy regulations allow a pharmacist to transfer a non-controlled prescription one time between pharmacies [15]. After that transfer, refills must come from the receiving pharmacy.

The prescriber from another state cannot continue prescribing to an Idaho address without holding an active Idaho prescriber license or practicing under Idaho's interstate compact provisions. The Interstate Medical Licensure Compact (IMLC) and the Nurse Licensure Compact (NLC) both include Idaho. A physician or NP in a compact member state can apply for expedited Idaho prescribing authority within 30 days in most cases, allowing continuity of care without requiring a new evaluation from an Idaho provider [5].

Patients in this situation should ask their out-of-state prescriber to apply for Idaho compact licensure or to refer them to an Idaho-licensed telehealth provider who can conduct a brief transition visit, review prior records, and issue a new Idaho prescription. The transition visit is typically shorter (10 to 15 minutes) than an initial evaluation because the diagnosis is already documented.

Managing Nausea and Blood Pressure With Vyleesi

Nausea is the most frequently reported adverse effect of bremelanotide. In the RECONNECT trials, 40.0% of bremelanotide-treated patients reported nausea compared with 1.3% in the placebo group [1]. For most patients, nausea peaks within 1 hour of injection and resolves within 2 hours without treatment. Administering bremelanotide on an empty stomach worsens nausea; the FDA label recommends eating a light meal at least 30 minutes before injection [2].

Ondansetron 4 mg orally (available by separate prescription) can be taken 30 minutes before the bremelanotide injection to reduce nausea severity. This off-label co-prescription is commonly used in clinical practice, though it adds a second prescription and cost for Idaho patients [7]. The American College of Obstetricians and Gynecologists notes that nausea-related discontinuation accounted for 7.4% of dropouts in the RECONNECT program, which remains the primary reason patients stop the medication [3].

Blood pressure rises transiently by an average of 6 mmHg systolic for approximately 12 hours after each dose [2]. Women with a resting blood pressure at or above 130/80 mmHg should have this discussion explicitly with their prescriber before starting. The FDA label does not classify hypertension as an absolute contraindication but recommends caution and blood pressure monitoring in women with baseline hypertension or cardiovascular risk [2]. The American Heart Association's blood pressure classification places readings above 130/80 mmHg in the Stage 1 hypertension range, which warrants individual risk-benefit discussion [16].

Flushing occurs in 20.3% of bremelanotide-treated patients vs. 3.0% placebo in RECONNECT, typically appearing as facial warmth and redness within 1 hour of injection and resolving without intervention [1].

Cost Comparison: Branded Vyleesi vs. Compounded Bremelanotide in Idaho

The branded Vyleesi auto-injector carries a wholesale acquisition cost near $999 per unit as of 2025 [10]. With the Palatin savings card, commercially insured patients pay as low as $99 per auto-injector, and most patients use one to two injectors per month based on sexual activity frequency. Uninsured patients who do not qualify for manufacturer assistance face the full cost.

Compounded bremelanotide from a licensed Idaho 503A pharmacy typically ranges from $80 to $200 per vial depending on the concentration and volume prepared, making it the most accessible option for cash-pay patients [10]. The trade-off is that compounded products do not undergo the same FDA manufacturing oversight as the branded product. Patients choosing the compounded route should confirm the pharmacy's PCAB accreditation (Pharmacy Compounding Accreditation Board) or verify a current Idaho Board of Pharmacy license [11].

Telehealth platform fees add to the total cost. Initial consultation visits for HSDD range from $75 to $150 on most cash-pay platforms. Monthly follow-up fees, where charged, range from $25 to $75. Some platforms bundle consultation and medication dispensing into a monthly subscription fee of $149 to $249 that includes the compounded drug and prescriber oversight [10].

The annual cost of Vyleesi therapy at two injectors per month ranges from approximately $2,376 with the manufacturer savings card to approximately $24,000 at list price without assistance, making insurance coverage or compounding access a practical necessity for most Idaho patients.

Setting Expectations: What Vyleesi Can and Cannot Do

Bremelanotide treats generalized, acquired HSDD. It is not approved for situational low desire (desire that is low only in specific contexts or with a specific partner), lifelong low desire (present since sexual debut), or HSDD secondary to an unresolved relationship conflict [2]. The RECONNECT inclusion criteria required that participants had previously experienced normal sexual desire before the onset of HSDD, confirming the "acquired" qualifier [1].

The drug does not increase testosterone, estrogen, or any gonadal hormone. It does not treat vaginal dryness, pain with intercourse (dyspareunia), or orgasm disorders. Patients who present with these additional concerns may need a multi-pronged approach: bremelanotide for desire, topical estrogen or ospemifene for vaginal atrophy, and pelvic floor physical therapy for dyspareunia [3].

Psychological and relational contributors to HSDD do not resolve with bremelanotide alone. The Endocrine Society guideline recommends concurrent psychotherapy or sex therapy for women whose HSDD has a significant psychological component [14]. Prescribers who identify depression, anxiety, or relationship distress in the HSDD evaluation should address those concurrently rather than relying on pharmacotherapy as the sole intervention.

The FSDS-DAO score at 8 weeks provides an objective benchmark for treatment response. Women who score meaningfully lower (reduced distress) at week 8 relative to baseline are considered responders. The FDA label defines "no improvement" as the threshold for discontinuation at 8 weeks [2]. Idaho patients should complete a written or digital FSDS-DAO at their 8-week follow-up visit rather than relying on a general subjective report, because clinician-documented outcome data also supports any future insurance appeal.